Micro-RNA (miRNA)-based therapies are an emerging class of cancer therapies with many potential applications in the field. Because of the broad effects miRNAs can have on different cells and tissues, a network science-based approach is well-equipped to evaluate and identify miRNA candidates and combinations of candidates for the repression of key oncogenic targets. Methods: We first characterized 6 Ewing sarcoma cell lines using paired mRNA and miRNA sequencing. We then estimated a measure of tumor state, which we term network potential, based on both the mRNA gene expression and the underlying protein-protein interaction network in the tumor. Next, we ranked mRNA targets based on their contribution to network potential. After identifying these mRNA targets, we identified miRNAs and combinations of miRNAs that preferentially act to repress these targets. Results: We identified TRIM25, APP, ELAV1, RNF4, XPO1 as ideal protein targets for Ewing sarcoma therapy. Using miRNA-mRNA target mappings, we identified miR-3613-3p, let-7a-3p, miR-300, miR-424-5p, and let-7b-3p as the optimal miRNAs for preferential repression of these targets. Discussion: In this work, we applied a novel pipeline for identification of miRNA candidates for cancer therapy, using Ewing sarcoma as a model system. 2 work has highlighted the critical importance of miRNAs in the development and maintenance of the cancer phenotype 1-3 . 3 MiRNA deregulation has been implicated in the development of each of the hallmark features of cancer, and restoration of 4 expression of some of these critical downregulated miRNAs has been studied as a potential treatment for several different 5 cancers 3-5 . In particular, in the past decade, anti-sense oligonucleotide inhibitors of the STAT3 transcription factor have shown 6 promise in the settings of lymphoma 6, 7 and neuroblastoma 8 . MiR-34 has shown to be effective in pre-clinical studies for 7 treatment of both lung cancer 9-11 and prostate cancer 12 . Finally, mir-34 and let-7 combination therapy has been shown to be 8 effective in pre-clinical studies of lung cancer 11 .
Introduction 1
MicroRNA (miRNA)-based treatments, including anti-sense oligonucleotides, are an emerging class of cancer therapy 1 . Recent Figure 1 . Cartoon describing rationale for focusing on miR combination therapy. With single-agent therapy, both target mRNA and non-target mRNA are inhibited an equal amount, potentially resulting in toxicity due to off-target effects. With miRNA combination therapy, the common target mRNA is inhibited to a greater degree than any individual non-target miRNA. calculated using the protein interaction network of human cells and relevant transcriptomics data 17 . Gibbs free energy has 20 been correlated with a number of cancer-specific outcomes, including cancer grade and patient survival 18 . Additionally, they 21 leveraged Gibbs and other network measures to identify personalized protein targets for therapy in a dataset of low-grade glioma 22 patients from The Cancer Genome Atlas (TCGA) 17 . Previous work has also highlighted the critical importance of miRNAs to 23 maintenance and development of the oncogenic phenotype, and demonstrated the utility of applying miRNA-mRNA mappings 24 3 . 25 Building on these works, we developed a novel computational pipeline for the identification of miRNA-based therapies for 26 cancer using Ewing sarcoma as a model system. Ewing sarcoma is a rare malignancy arising from a gene fusion secondary to 27 rearrangements involving the EWS gene 20 . There are 200-300 reported cases each year in the United States, disproportionately 28 affecting children 21 . Ewing sarcoma is extremely prone to developing resistance to available therapies 2 , making it an ideal 29 system on which to develop novel therapies to treat resistant tumors or avoid the development of resistance altogether. We characterized six previously described Ewing sarcoma cell lines 22 -A673, ES2, EWS502, TC252, TC32, and TC71-using 33 matched mRNA and miRNA sequencing. We then defined a measure of tumor state, which we term network potential (Equation 34 1), based on both mRNA gene expression and the underlying protein-protein interaction network (PPI). Next, we ranked mRNA 35 targets based on their contribution to network potential of each cell line, aiming to approximate the relative importance of 36 each mRNA to network stability. Relative importance of each mRNA to network stability was determined by calculating the 37 change in network potential of each network before and after in silico repression of each mRNA (∆G, described in Section 1.5).
38
After identifying these mRNA targets, we then identified miRNA that preferentially acted to repress the most influential of 39 the ranked mRNA targets, with the aim of defining synthetic miRNA-based therapy for down-regulation of these targets. Our 40 computational pipeline is schematized in Figure S1 . 41
Data sources
Using this mapping as well as our ranked list of promising gene candidates for repression from our network analysis, we 98 were able to identify a list of miRNA that we predict would maximally disrupt the Ewing sarcoma cell signaling network when 99 introduced synthetically. To rank miRNA targets, we first identified all the genes on the full target list that a given miRNA was 100 predicted to repress (described in Section 1.5). Next, we summed the predicted ∆G when each of these genes was repressed in 101 silico to generate the maximum potential disruption that could be achieved if a given miRNA were introduced synthetically 102 into an Ewing sarcoma tumor. We then ranked miRNA candidates in descending order of the maximum predicted network 103 disruption.
104
In addition, we identified combinations of miRNAs with overlapping mRNA targets in order to identify promising miRNA 105 cocktails. miRNA cocktails may effectively destabilize cancer cell signaling networks while avoiding systemic toxicities. To do 106 so, we first identified a subset of key mRNA targets to focus on. For this analysis, we limited our list of targets to those that 107 were previously causally implicated in cancer 35 . We then used our miRNA-mRNA mappings to identify a cocktail of miRNAs 108 in which every miRNA was predicted to repress > 2 of the top 5 mRNA transcripts ranked by predicted ∆G when each of these 109 genes was repressed in silico.
110 Figure 2 . We performed matched mRNA and miRNA sequencing for 6 Ewing sarcoma cell lines. A: Clustered miRNA expression. B: Clustered mRNA expression. Rows and columns were clustered using the complete linkage method with euclidean distance as the distance metric. Ewing sarcoma cell line is represented on the x axis while mRNA/miRNA is represented on the y axis.
Results

111
We performed matched mRNA and miRNA sequencing on six Ewing sarcoma cell lines: A673, ES2, EW502, TC252, TC32, 
Network Overview
115
We calculated the network potential, a unitless measure of cell state, for each protein in the cell signaling networks for each 116 of the six Ewing sarcoma cell lines in our experiment. An overview of the total network potential for each cell line and 117 evolutionary replicate compared to total mRNA expression is presented in Figure 3 . The density plots of network potential and 118 mRNA expression look markedly different ( Figure 3A and Figure 3B ), indicating that network potential describes different 119 features of a cell signaling network compared to mRNA expression alone. Notably, network potential and mRNA expression 120 for these cell lines is stable across different biological replicates, as demonstrated by the low interquartile range ( Figure 3C and 121 3D). There were modest differences in both mean expression and network potential across cell lines ( Figure 3C and 3D). The 122 global average network potential across all samples was −3.45 × 10 5 with a standard deviation of 1725. 
Identification of Protein Targets
124
We identified TRIM25, APP, ELAV1, RNF4, and XPO1 as top 5 targets for therapy for each of the 6 cell lines based on the 125 degree of network disruption induced when each gene was modeled as repressed. There was a high degree of concordance 126 between cell lines among the top predicted targets, indicating that these targets may be conserved across Ewing sarcoma 127 (Table S1 ). Of the top ten predicted targets, 9 are among the top 10 targets for all 6 cell lines. Some of these identified genes may be essential housekeeping genes highly expressed in all or most cells in the body, making 129 them inappropriate drug targets. TRIM25, and ELAV1, for example, are involved in protein modification and RNA binding, Table 1 . Top cancer-associated protein targets for each cell line. We ranked potential targets by predicted change in network potential when each protein was modeled as repressed, limited to proteins causally associated in cancer according to the Cosmic database. Proteins that appear in the same position for ≥ 3 cell lines are bolded. high degree of concordance in the top predicted miR candidates between cell lines (Table 2) . It should also be noted that we 150 were able to identify a substantial number of miRNA with potential activity against the Ewing sarcoma cell signaling network.
151
We identified 27 miRNAs with a predicted network potential disruption of greater than 10, 000. For comparison, the largest 152 network change in network potential that could be achieved with a single gene repression across all cell lines was just 2064 miRNA that inhibits the most targets might not necessarily be the best drug target. We therefore sought to identify combinations 156 of miRNAs that individually repressed key drug targets. Our hypothesis is that by giving a cocktail of miRNAs with predicted Figure 4 . Protein targets ranked by contribution to network stability. When averaging across cell lines, XPO1, LMNA, EWSR1, HSP90AA1, and NTRK1 were identified as the most important proteins in the Ewing sarcoma cell signaling network (when limiting our analysis to proteins causally implicated in cancer 35 ). When each protein was simulated as completely repressed, network potential was increased by 656, 458, 431, 427, and 403, respectively. It is reassuring that EWSR1, the kinase associated with Ewing sarcoma development, is identified as highly influential in the cell signaling network by this method.
The optimal number of targets for designing an effective miRNA cocktail is unclear. We present these results to highlight the 170 flexibility of our method for empirically designing miRNA-based therapies for the treatment of cancer. Validation of individual 171 regimens in vitro and in vivo is necessary to establish clinical utility for any of the regimens identified with this method. In this work, we described a novel pipeline for the identification of miRNA candidates for cancer therapy, using Ewing sarcoma 174 as a model system. Our pipeline can also be used to identify targetable proteins that are important to the stability of a cell 175 signaling network. First, we performed matched mRNA and miRNA sequencing on six Ewing sarcoma cell lines (available 176 soon on the sequence read archive). We then defined a metric of cell state, network potential. Using network potential, we 177 identified the most important proteins in the cell signaling network for each of the 6 cell lines. Notably, this set of proteins was 178 strongly enriched in genes involved in the canonical miRNA biogenesis pathway 3 , which supports the crucial role miRNA play 179 in modulation of cell signaling.
180
To our knowledge, ours is the first generic pipeline that analyzes RNA sequencing data to generate protein targets and TC252  ES2  A673  TC32  EWS502  TC71  1 let-7a-3p let-7a-3p let-7a-3p let-7a-3p miR-4692 let-7a-3p 2 miR-4692 miR-4692 miR-4692 miR-4692 let-7a-3p miR-4692 3 let-7b-3p let-7b-3p let-7b-3p let-7b-3p let-7b-3p let-7b-3p 4 let-7f-1-3p let-7f-1-3p let-7f-1-3p let-7f-1-3p let-7f-1-3p let-7f-1-3p 5 miR-9-5p miR-483-3p miR-9-5p miR-9-5p miR-483-3p miR-483-3p As described in the main text, we ranked proteins according to their contribution to network stability by calculating the change 342 in network potential following complete in silico repression of each protein. In the main text, we limited our analysis to proteins 343 that had been causally implicated in cancer according to the cosmic database 35 . Here, we present the top 50 proteins (when 344 network potential for all 6 cell lines was averaged) ranked by contribution to network stability, not limited to proteins that were 345 causally implicated in cancer ( Figure S2 ).
346
We also analyzed each cell line individually to identify the top protein targets for each cell line. In the main text, we limited 347 this analysis to proteins that had been causally implicated in cancer 35 . Here, we present the top protein targets for each cell line, 348 not limited to those proteins that had previously been causally implicated in cancer (Table S1). 5t   TC252  ES2  A673  TC32  EWS502 TC71  1 TRIM25 TRIM25 TRIM25 TRIM25 TRIM25 TRIM25  2 APP  APP  APP  APP  APP  APP  3 ELAVL1 ELAVL1 ELAVL1 ELAVL1 ELAVL1 ELAVL1  4 RNF4  RNF4  RNF4  RNF4  RNF4  RNF4  5 XPO1  XPO1  XPO1  XPO1  XPO1  XPO1  6 NXF1  NXF1  NXF1  NXF1  NXF1  NXF1  7 UBC  TNIP2  UBC  UBC  UBC  UBC  8 TNIP2  UBC  TNIP2  TNIP2  TNIP2  TNIP2  9 MOV10  MOV10  MOV10  MOV10  MOV10  MOV10  10 RNF123 RNF123 RNF123 LMNA  RNF123 RNF123   Table S1 . Top protein targets for each cell line. We ranked potential targets by predicted change in network potential when each protein was modeled as repressed. Figure S2 . Protein targets ranked by contribution to network stability. When averaging across cell lines, TRIM25, APP, ELAV1, RNF4, and XPO1 were identified as the most important proteins in the Ewing sarcoma cell signaling network. When each protein was simulated as completely repressed, network potential was increased by 1, 914, 1, 739, 1, 445, 792, and 656, respectively. It is notable that EWSR1, the kinase associated with Ewing sarcoma development, is considered highly influential in the cell signaling network by this method. Genes that have previously been causally implicated in cancer according to the Cosmic database are highlighted in red 35 .
As described in the main text, miR-3613-3p was the top miR for predicted repression of the Ewing sarcoma cell signaling 357 network across all 6 cell lines. Here we present the full list of the 144 distinct mRNA miR-3613-3p is predicted to repress 358 among our full list of protein targets (Table S3 ). The full list of protein targets was generated by ranking all proteins in the cell 359 signaling network according to network potential and taking the top 5% of all proteins. Table S3 -continued from previous page   miR-3613-3p targets  12  CBX5  13  CCAR2  14  CDC27  15  CDC42  16  CDC5L  17  CDC73  18  CEP44  19  CPSF6  20  CREBBP  21  CSE1L  22  CSNK1A1  23  CTNNB1  24  CTTN  25  CUL3  26  DAZAP1  27  DCUN1D1  28  DDX6  29  EIF3A  30  ELAVL1  31  EP300  32  EZR  33  FBXW7  34  FGFR1  35  FUBP1  36  G3BP1  37  G3BP2  38  GFPT1  39  GOLT1B  40  GSK3B  41  HDAC3  42  HIF1A  43  HNRNPA3  44  HNRNPF  45  HNRNPH1  46  HNRNPU  47  HP1BP3  48  HUWE1  49  IPO7  50  KIF5B  51  KRAS  52  LARP1  53  LMNB1  54  MAP3K7  55  MCM4  56  MDM2  57  MTCH2  58  NAP1L1  59  NCBP1  60  NDUFA4  61  NEDD1  62  NF2  63 NOTCH1 Continued on next page 15/18 Table S3 -continued from previous page   miR-3613-3p targets  64  NR3C1  65  NUDT21  66  PDIA3  67  PIK3R1  68  POLR2A  69  PPP1CB  70  PRKAA1  71  PRKAR1A  72  PRPF40A  73  PTGES3  74  PTK2  75  RAD23B  76  RB1  77  RBMX  78  RBPJ  79  RC3H1  80  RDX  81  REST  82  RNF2  83  RPL15  84  SERBP1  85  SET  86  SIN3A  87  SKP2  88  SMAD2  89  SMAD4  90  SMAD9  91  SMARCAD1  92  SOAT1  93  SP1  94  SPAG9  95  SPTBN1  96  SREK1  97  SRPK1  98  SRPK2  99  SRRM1  100  SRSF2  101  SRSF5  102  STAU1  103  SUMO1  104  SUMO2  105  SYNCRIP  106  TBL1XR1  107  TCEA1  108  TCF3  109  TCF4  110  TES  111  TOP1  112  TUBB  113  UBA52  114  UBE2D3  115 USP47 Continued on next page 16/18 Table S3 -continued from previous page   miR-3613-3p targets  116  VAPA  117  XPO1  118  YAP1  119  YWHAH  120  YWHAZ  121  ZDHHC17  122  ZWINT  123  TERF2  124  CCND2  125  IGF2BP3  126  KHSRP  127  RICTOR  128  DPYSL2  129  GNB1  130  KMT2A  131 LGR4 132  SSR3  133  TXLNA  134  SMC2  135  TSNAX  136  IGF1R  137  LAMP2  138  CCNT1  139  ATXN1  140  CIRBP  141  CLINT1  142  KPNA1  143  XRN1  144 GOPC
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